Fundraising September 15, 2024 – October 1, 2024 About fundraising
19

MKNK2 is a valid target of miR-125b in breast cancer

Year:
2016
Language:
english
File:
PDF, 1.24 MB
english, 2016
25

Lasting Controversy on Ranibizumab and Bevacizumab

Year:
2011
Language:
english
File:
PDF, 457 KB
english, 2011